Business Model MAB Discovery intends to engage in collaborations with partners using its robust platform to discover, isolate and characterize monoclonals of unprecedented quality in terms of potency, functionality and epitope coverage. MAB Discovery can go all the way from immunization to delivery of well-characterized cell lines producing clinical candidates. Hand off of intermediates at any stage is also possible. Furthermore, the partner also has the option to engage the rest of PPD's extensive array of drug development services, including BioDuro. MAB Discovery, per se, does not intend to engage in further development. Because of the Company's unique corporate relationship with PPD, Inc., MAB Discovery does not need to pursue traditional IP licensing deals and instead is offering flexible and straightforward business terms: technology access fees , research support, success milestones, no royalties, and no gate-keeping. Buy-out options are also available. For more information please contact: stephan.fischer@mabdiscovery.com Business Model Partners About Us Technology Partnering News Contact Careers HomeImpressumSite Map